← Back to Search

EsoCheck + EsoGuard for Barrett's Esophagus and Esophageal Adenocarcinoma (ESOGUARDBE2 Trial)

N/A
Recruiting
Research Sponsored by Lucid Diagnostics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up per subject through study completion which is up to approximately 5 weeks
Awards & highlights

ESOGUARDBE2 Trial Summary

This trial will compare a new BE/EAC detection system to the current standard of care.

Eligible Conditions
  • Esophageal Cancer
  • Barrett's Esophagus

ESOGUARDBE2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~per subject through study completion which is up to approximately 5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and per subject through study completion which is up to approximately 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Efficacy
Secondary outcome measures
Secondary Efficacy
Other outcome measures
Safety outcome of EsoCheck Device (510k cleared, non-invasive, esophageal cell collection device) on all patients who undergo the device procedure.

ESOGUARDBE2 Trial Design

1Treatment groups
Experimental Treatment
Group I: EsoCheck and EsoGuard vs. EGD with or without biopsiesExperimental Treatment2 Interventions
All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Esophagogastroduodenoscopy
2017
Completed Phase 3
~980

Find a Location

Who is running the clinical trial?

Lucid Diagnostics, Inc.Lead Sponsor
5 Previous Clinical Trials
1,257 Total Patients Enrolled
Randy B, MSStudy DirectorLucid Diagnostics, Inc.
Michelle McDermottStudy DirectorLucid Diagnostics, Inc.
1 Previous Clinical Trials
145 Total Patients Enrolled

Media Library

EsoCheck Clinical Trial Eligibility Overview. Trial Name: NCT04295811 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
2020. "Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04295811.
~97 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top